White House Selects Domestic Policy Aide Heidi Overton to Direct Food and Drug Administration

WASHINGTON, DC — President Donald Trump announced Wednesday the formal nomination of Dr. Heidi Overton, deputy director of the White House Domestic Policy Council, to serve as Commissioner of the U.S. Food and Drug Administration.

Background and Executive Health Priorities

Dr. Overton, a surgical clinician trained at Johns Hopkins University with a doctorate in clinical investigation, previously served as chief policy officer at the America First Policy Institute. In executive statements, administration officials praised Overton's close coordination with Health and Human Services leadership on drug pricing transparency, clinical trial streamlining, and agricultural additives review.

If confirmed by the Senate, Dr. Overton will assume leadership of an agency overseeing an annual budget exceeding $6.8 billion and regulating roughly 20 percent of total U.S. consumer spending, spanning pharmaceuticals, medical devices, biologics, and commercial food supplies.

Confirmation Stakes and Congressional Reactions

The nomination immediately drew contrasting responses along party lines on Capitol Hill. Senate Health, Education, Labor, and Pensions Committee leaders signaled that confirmation hearings will focus intensively on pharmaceutical approval timelines, dietary supplement regulations, and the agency's stance on reproductive healthcare medications.

Ranking Democratic members voiced scrutiny over past policy papers regarding federal drug safety oversight, while Republican committee members emphasized Overton's clinical research credentials and commitment to accelerating treatment access for rare pediatric illnesses.

Next Steps in Senate Confirmation Process

Senate Majority Leader John Thune confirmed that formal nomination papers have been referred to the Senate HELP Committee. Preliminary confirmation hearings are scheduled to commence in late September following the congressional recess.